Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 4/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.51 |
| ▸ | BACE1 | P56817 | 4/20 | 0.50 |
| ▸ | CCKAR | P32238 | 1/20 | 0.47 |
| ▸ | CCKBR | P32239 | 1/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.47 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29443515 | 1.00 | OPRK1 (0.51) | OPRK1OPRM1OPRD1BACE1CCKAR | |
| SCHEMBL30397713 | 0.92 | OPRM1 (0.53) | OPRK1OPRM1OPRD1BACE1CTSD | |
| SCHEMBL29856025 | 0.90 | TFPI (0.56) | OPRK1OPRM1OPRD1CCKBR | |
| SCHEMBL29569118 | 0.89 | OPRK1 (0.54) | OPRK1OPRM1OPRD1BACE1CTSD | |
| SCHEMBL30420308 | 0.89 | OPRD1 (0.52) | OPRK1OPRM1OPRD1BACE1CCKBR | |
| SCHEMBL30733256 | 0.87 | OPRK1 (0.58) | OPRK1OPRM1BACE1CTSDBACE2 | |
| SCHEMBL29789569 | 0.86 | OPRK1 (0.54) | OPRK1OPRM1OPRD1 | |
| SCHEMBL30435360 | 0.85 | OPRK1 (0.54) | OPRK1OPRM1OPRD1BACE1CTSD | |
| SCHEMBL31211792 | 0.84 | MMP2 (0.48) | BACE1CCKARCCKBR | |
| SCHEMBL30397813 | 0.84 | BACE1 (0.60) | OPRK1BACE1CTSDBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390468-A1 | SURVIVIN AND MAGE-A9 DUAL-TARGETED IMMUNOTHERAPY | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2024-11-28 | — | — | US | disclosed |
| US-20240288423-A1 | PEPTIDE EXCHANGE SYSTEM AND METHOD | MEDICAL & BIOLOGICAL LABORATORIES CO., LTD (JP) | 2024-08-29 | — | — | US | disclosed |
| EP-4408460-A1 | SURVIVIN AND MAGE-A9 DUAL-TARGETED IMMUNOTHERAPY | BioVaxys Inc. (US) | 2024-08-07 | — | — | EP | disclosed |
| US-12044680-B2 | Peptide exchange system and method | MBL INTERNATIONAL CORP. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2023052842-A1 | SURVIVIN AND MAGE-A9 DUAL-TARGETED IMMUNOTHERAPY | IMMUNOVACCINE TECHNOLOGIES INC. (CA) | 2023-04-06 | — | — | WO | disclosed |
| CN-109642903-B | Peptide exchange system and method | MBL国际公司 | 2023-02-28 | — | — | CN | disclosed |
| CN-107531736-B | Lipid A mimetics, methods of making and uses thereof | 免疫疫苗科技公司 | 2022-04-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390468-A1 | SURVIVIN AND MAGE-A9 DUAL-TARGETED IMMUNOTHERAPY | BIRC5, BIRC2, BIRC7 | OPRK1 4821/4885OPRM1 4809/4885OPRD1 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.